Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Inflammatory and Immune-related disorders

28th Oct 2025

Plain language summary: AI-based monitoring of geographic atrophy treatment with pegcetacoplan

25th Feb 2025

A plain language summary of Part A of the LILAC study of litifilimab for treating systemic lupus erythematosus

25th Feb 2025

A plain language summary of Part B of the LILAC study on litifilimab for treating cutaneous lupus erythematosus

22nd Nov 2024

Exploring pain changes in women with uterine fibroids treated with relugolix combination therapy

23rd Sep 2024

Plain language summary of the BICSTaR study: one-year results of bictegravir, emtricitabine, and tenofovir alafenamide for HIV treatment

16th Sep 2024

Plain language summary of the NefIgArd trial: Nefecon for treating patients with immunoglobulin A nephropathy

16th Sep 2024

Plain language summary of the phase 3 study on Leniolisib treatment for people with activated PI3K delta syndrome (APDS)

6th Sep 2024

A plain-language summary of two 5-Year studies on bictegravir/emtricitabine/tenofovir alafenamide in people with HIV

Atopic dermatitis (AD) is a chronic (long-lasting) skin disease that leads to dry, itchy, and swollen red spots, which can also be painful and flare up at any time. Some people with AD have a high number of eosinophils, a type of white blood cell, which are associated with worse disease. Medicated creams and lotions, prescribed by health care providers, are meant to reduce the symptoms of AD. For some people, these creams and lotions do not work. Benralizumab injection is a medication that reduces and removes eosinophils. A clinical trial called HILLER tested benralizumab to see if there was a difference in symptoms of AD after reducing or removing eosinophils. This article explains how benralizumab reduced eosinophils and the effect it had on AD symptoms in the HILLIER study.
29th May 2024

A plain language summary of the HILLIER study: Treating moderate-to-severe atopic dermatitis with benralizumab

Generalized pustular psoriasis (shortened to GPP) is a rare, potentially life-threatening disease in which pus-filled blisters or pustules may suddenly form all over the body. The drug spesolimab has been approved to treat worsening GPP (known as flares) in many countries. However, it was not known if spesolimab could prevent the symptoms of GPP. This summary reports the results from a clinical study called Effisayil™ 2, that was done to understand if spesolimab was a safe and effective way to prevent flares in people with GPP. In the study, 123 participants, recruited in 20 different countries, were given one of three different doses of spesolimab (low, medium, or high) or a non-active medicine (placebo) over 48 weeks.
27th Feb 2024

A plain language summary looking at spesolimab treatment for the prevention of flares in people with generalized pustular psoriasis (GPP)

n this article, we summarize results from the ongoing phase 3 CheckMate 76K clinical study published online in Nature Medicine in October 2023. The study goal was to learn whether nivolumab works as an adjuvant therapy (that is, helps to keep cancer from coming back when it is given after surgery) for stage 2 melanoma (skin cancer) that has not spread to other parts of the body. Nivolumab is an immunotherapy that activates a person's immune system so it can destroy cancer cells. In melanoma, staging describes the severity of the cancer. Melanoma staging ranges from 0 (very thin and confined to the upper layer of the skin) to 4 (spread to distant parts of the body), with earlier stages removed by surgery. The people in this study had stage 2 melanoma that had not spread to the lymph nodes or other organs in the body.
27th Feb 2024

A plain language summary looking at nivolumab that is given after stage 2B/2C melanoma is removed by surgery

This is a summary of two publications. One publication is about the GATHER1 study, which was published in the journal Ophthalmology in 2021. The other publication is about the GATHER2 study, which was published in the journal The Lancet in 2023. Both studies included adult participants with geographic atrophy (GA). GA is an advanced form of dry age-related macular degeneration (dry AMD). The participants in both studies each received treatment in one of their eyes. In both studies, the researchers wanted to learn if avacincaptad pegol (ACP) could help to slow the worsening of the participants’ GA over time.
25th Jan 2024

GATHER1 and GATHER2 studies: a plain language summary looking at whether avacincaptad pegol works and is safe in people with geographic atrophy

This plain language summary explains, in simple terms, the results of a study from 2022 discussing a biosimilar medicine called GP2017 (called SDZ-ADL in this summary, sold as Hyrimoz®). This medicine is used to treat people with inflammatory conditions. This study investigated a new, high-concentration formulation of GP2017 (SDZ-ADL-HCF) in order to show that the high concentration option acts the same way in the body as SDZ-ADL
22nd Jan 2024

Two different concentrations of GP2017 (a biosimilar medicine) are associated with similar drug levels in the body- a plain language summary

This is a summary of an article published in The New England Journal of Medicine about the EPITOPE clinical study, which tested a skin patch called ViaskinTM Peanut 250 μg (micrograms) as a treatment option for peanut allergy in children aged 1 through 3 years. The patch is a form of epicutaneous immunotherapy (EPIT), which is a new approach to allergen immunotherapythat delivers a small amount of peanut protein to the immune system through the skin
22nd Jan 2024

A plain language summary of epicutaneous immunotherapy with Viaskin™ Peanut in toddlers

Severe aplastic anemia (SAA) and very severe aplastic anemia (vSAA) are blood diseases of the bone marrow. If a suitable donor for bone marrow transplant as initial treatment is unavailable, standard immunosuppression is used. Standard immunosuppression treatment includes horse antithymocyte globulin (hATG) and cyclosporin A (CsA). This summary investigated the results of standard immunosuppression treatment (Group A) versus standard immunosuppression treatment with a medication called eltrombopag (Group B) in participants with SAA and vSAA. Eltrombopag is a medicine that improves the blood platelet level and is taken by mouth (orally).
22nd Jan 2024

A plain language summary of the RACE study looking at adding eltrombopag to standard treatment of severe aplastic anemia

This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the treatment of severe, uncontrolled asthma in people aged 12 and older. The results of these 2 studies, called PATHWAY and NAVIGATOR, formed the basis for tezepelumab’s approval for use. Tezepelumab is a type of biologic treatment called an antibody. It works by blocking a key first step in the body’s chain reaction leading to inflammation in the airways of people with severe asthma.The clinical studies were done to learn if tezepelumab can be used to treat people with severe, uncontrolled asthma and to find out about its safety. In both studies, tezepelumab was compared with the placebo
29th Sep 2023

A plain language summary of the PATHWAY and NAVIGATOR studies: tezepelumab for the treatment of severe asthma

This is a summary of the results of the ALLEGRO phase 2b/3 clinical trial, originally published in The Lancet. ALLEGRO-2b/3 looked at how well and safely the study medicine, ritlecitinib, works in treating people with alopecia areata ('AA' for short). The immune system protects your body from outside invaders such as bacteria and viruses. AA is an autoimmune disease, meaning a disease in which one’s immune system attacks healthy cells of the body by mistake. In AA, the immune system attacks hair follicles, causing hair to fall out.AA causes hair loss ranging from small bald patches to complete hair loss on the scalp, face, and/or body. Ritlecitinib is a medicine taken as a pill every day, by mouth, that is approved for the treatment of severe AA. It blocks processes that are known to play a role in causing hair loss in patients with AA.
6th Jul 2023

Plain Language Summary: ritlecitinib treatment for adults and adolescents with alopecia areata

This summary explains the findings from a recent investigation that combined the results of over 1000 people from three clinical studies to understand the safety of evobrutinib.Evobrutinib is an oral medication (taken by mouth), being researched as a potential treatment for multiple sclerosis (MS). This medication was also investigated in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).Over 1000 people have taken evobrutinib as part of three separate phase 2 clinical studies. These studies looked at how much of the drug should be taken, how safe the drug is, and how well it might work for treating a certain medical condition.
27th Jun 2023

Plain Language Summary: what can clinical studies tell us about evobrutinib, a potential treatment for multiple sclerosis

Atopic dermatitis (AD, also called atopic eczema) is a skin disease that that can affect a person for a long time and causes red or flaky skin that can be itchy and uncomfortable. Healthcare providers can prescribe medicated creams and ointments to reduce the visible signs and symptoms of AD, but these treatments are not always enough to keep it under control. A new medicine called abrocitinib is taken every day as a tablet. Abrocitinib works by slowing a part of the body’s defense mechanism, called immune response, that is not functioning properly in AD. The clinical study described in this plain language summary, called JADE DARE, investigated how well and how safely 26 weeks of treatment with abrocitinib worked in adults with AD compared to an injected medicine, called dupilumab, that is also approved for AD
2nd Jun 2023

Plain Language Summary: comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms

This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-1, which looked at a new treatment called deucravacitinib for plaque psoriasis. Plaque psoriasis appears on the body as round or oval raised patches (called plaques) typically covered by scales. This can cause the skin to itch, crack or bleed, and the associated itching and pain can make it difficult to perform basic everyday tasks. Living with psoriasis can cause emotional distress. Treatments are available, but some do not always reduce the symptoms of psoriasis, some may need to be injected or taken multiple times a day, and some may have side effects. Researchers are looking for new treatments that are more effective, convenient to take, and have acceptable safety and tolerability.
23rd May 2023

Plain Language Summary: POETYK PSO-1 study, treatment of plaque psoriasis with deucravacitinib

This is a summary of a paper published in a medical journal that describes the results of a study called POETYK PSO-2, which investigated a new treatment for plaque psoriasis. Plaque psoriasis appears on the body as dry, discolored, patches of skin that can be flaky and covered in scales. This can make the skin itch, crack or bleed and make it difficult for people with psoriasis to perform basic everyday tasks. Treatments are available, but some do not always reduce symptoms or may need to be injected or taken multiple times a day, which can be difficult to do, or can have undesirable side effects. Researchers are looking for new treatments for psoriasis
23rd May 2023

Plain Language Summary: treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study)

This Plain Language Summary of Publication article from Immunotherapy focusses on Eosinophil-associated diseases (EADs) which are a group of conditions in which eosinophils (a type of white blood cell) play a key role in the disease and how it develops. This summary will look at the key elements of good quality care and present an action plan to improve health and overall well-being for people with EADs.
17th May 2023

Plain Language Summary: principles for improving the care of people with eosinophil-associated diseases

1st Mar 2023

Plain language summary of the VOLTAIRE-CD study in people with moderate-to-severe active Crohn’s disease

20th Sep 2022

Plain language summary of the VOLTAIRE-RA study in patients with moderate-to-severe rheumatoid arthritis

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy